Wedge Capital Management L L P NC acquired a new stake in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH – Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm acquired 128,845 shares of the biopharmaceutical company’s stock, valued at approximately $2,190,000.
A number of other hedge funds have also recently bought and sold shares of the company. AQR Capital Management LLC bought a new stake in shares of Theravance Biopharma in the 1st quarter worth $101,000. Jane Street Group LLC lifted its position in shares of Theravance Biopharma by 169.2% during the first quarter. Jane Street Group LLC now owns 140,884 shares of the biopharmaceutical company’s stock valued at $1,258,000 after purchasing an additional 88,540 shares in the last quarter. Creative Planning bought a new position in shares of Theravance Biopharma during the second quarter valued at about $139,000. American Century Companies Inc. boosted its holdings in Theravance Biopharma by 6.8% during the second quarter. American Century Companies Inc. now owns 91,501 shares of the biopharmaceutical company’s stock worth $1,009,000 after purchasing an additional 5,794 shares during the last quarter. Finally, Invesco Ltd. boosted its holdings in Theravance Biopharma by 12.4% during the second quarter. Invesco Ltd. now owns 25,324 shares of the biopharmaceutical company’s stock worth $279,000 after purchasing an additional 2,789 shares during the last quarter. 99.10% of the stock is owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In other Theravance Biopharma news, SVP Rhonda Farnum sold 13,314 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $16.39, for a total transaction of $218,216.46. Following the sale, the senior vice president owned 232,457 shares in the company, valued at $3,809,970.23. This represents a 5.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Eli Samaha sold 37,799 shares of the firm’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $17.00, for a total value of $642,583.00. Following the completion of the transaction, the insider directly owned 9,174,453 shares of the company’s stock, valued at $155,965,701. The trade was a 0.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 350,011 shares of company stock worth $6,008,309 in the last three months. Insiders own 7.65% of the company’s stock.
Theravance Biopharma Stock Up 0.3%
Theravance Biopharma (NASDAQ:TBPH – Get Free Report) last announced its quarterly earnings results on Monday, August 10th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.18). The business had revenue of $20.73 million for the quarter, compared to analysts’ expectations of $22.49 million. Theravance Biopharma had a net margin of 51.58% and a negative return on equity of 0.77%. On average, sell-side analysts expect that Theravance Biopharma, Inc. will post 1.56 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several equities research analysts have commented on TBPH shares. JonesTrading lowered shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Monday, June 29th. Weiss Ratings upgraded Theravance Biopharma from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 3rd. BTIG Research lowered Theravance Biopharma from a “buy” rating to a “neutral” rating in a report on Monday, June 29th. HC Wainwright lowered Theravance Biopharma from a “buy” rating to a “neutral” rating and upped their target price for the company from $15.00 to $17.00 in a report on Tuesday, July 7th. Finally, Zacks Research raised Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating and seven have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $19.40.
Check Out Our Latest Analysis on TBPH
About Theravance Biopharma
Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.
Featured Stories
- Five stocks we like better than Theravance Biopharma
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Want to see what other hedge funds are holding TBPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Theravance Biopharma, Inc. (NASDAQ:TBPH – Free Report).
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
